Table 3.
Resistance patterns among the 84 Salmonella isolates
| Resistance patternsa | Prevalence, (n) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SE | ST | SG | SGP | OT | total | |||||||
| AMP | 0 | 3 | 2 | 7 | 1 | 13 | ||||||
| TCY | 0 | 0 | 1 | 0 | 0 | 1 | ||||||
| AMP | TCY | 1 | 1 | 1 | 5 | 1 | 9 | |||||
| AMP | CLS | 0 | 2 | 0 | 6 | 0 | 8 | |||||
| AMP | TGC | 0 | 0 | 0 | 1 | 0 | 0 | |||||
| AMP | CHL | 0 | 0 | 0 | 1 | 0 | 1 | |||||
| AMP | CHL | CLS | 0 | 0 | 0 | 2 | 0 | 2 | ||||
| AMP | CHL | STX | 0 | 2 | 0 | 0 | 0 | 2 | ||||
| AMP | MEM | CHL | 0 | 1 | 0 | 0 | 0 | 1 | ||||
| AMP | MEM | TCY | 1 | 0 | 0 | 0 | 0 | 1 | ||||
| AMP | TCY | CLS | 3 | 0 | 0 | 3 | 1 | 7 | ||||
| AMP | TCY | STX | 1 | 1 | 1 | 0 | 0 | 3 | ||||
| AMP | STX | CLS | 0 | 0 | 0 | 4 | 0 | 4 | ||||
| AMP | TCY | CHL | 0 | 0 | 3 | 1 | 0 | 4 | ||||
| AMP | CHL | STX | CLS | 1 | 0 | 0 | 0 | 0 | 1 | |||
| AMP | CTX | TCY | CHL | 0 | 0 | 2 | 0 | 0 | 2 | |||
| AMP | MEM | TCY | CLS | 1 | 0 | 0 | 0 | 0 | 1 | |||
| AMP | TCY | CHL | CLS | 0 | 0 | 2 | 3 | 1 | 6 | |||
| AMP | TCY | STX | CLS | 0 | 0 | 1 | 1 | 0 | 2 | |||
| AMP | TCY | CLS | TGC | 0 | 0 | 0 | 1 | 0 | 0 | |||
| AMP | GEN | STX | CLS | TGC | 0 | 0 | 0 | 1 | 0 | 1 | ||
| AMP | CTX | TCY | CHL | CLS | 0 | 0 | 1 | 2 | 0 | 3 | ||
| AMP | MEM | TCY | STX | CLS | 1 | 0 | 0 | 0 | 0 | 1 | ||
| AMP | TCY | CHL | CIP | STX | 2 | 0 | 0 | 0 | 0 | 2 | ||
| AMP | MEM | TCY | CHL | CLS | 1 | 0 | 0 | 0 | 0 | 1 | ||
| AMP | TCY | CHL | STX | CLS | 0 | 0 | 0 | 0 | 1 | 1 | ||
| AMP | TCY | CIP | STX | CLS | 1 | 0 | 0 | 0 | 0 | 1 | ||
| AMP | CTX | TCY | CHL | CLS | TGC | 0 | 0 | 1 | 0 | 0 | 0 | |
| AMP | TCY | CHL | CIP | STX | CLS | 0 | 1 | 0 | 0 | 0 | 1 | |
| AMP | MEM | TCY | CHL | CIP | STX | CLS | 1 | 0 | 0 | 0 | 0 | 1 |
aResistance breakpoints were gentamicin (GEN; ≥ 16 μg/mL), meropenem (MEM; ≥ 4 μg/mL), ampicillin (AMP; ≥ 32 μg/mL), cefotaxime (CTX; ≥ 4 μg/mL), colistin (CLS; ≥8 μg/mL), ciprofloxacin (CIP; ≥ 4 μg/mL), chloramphenicol (CHL; ≥ 32 μg/mL), tigecycline (TGC; ≥ 8 μg/mL), compound sulfamethoxazole (SXT; ≥4/76 μg/mL), and tetracycline (TCY; ≥ 16 μg/mL) (Clinical and Laboratory Standards Institute, 2017)